Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

James P. Thomas MD, PhD

James P. Thomas MD, PhD


Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology
Program: Hematology

Member of the Cancer Center


  • Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. (Miura JT, Xiu J, Thomas J, George B, Carron BR, Tsai S, Johnston FM, Turaga KK, Gamblin TC) Cancer Biol Ther 2015 May 4;16(5):764-9 PMID 25778705
  • Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. (Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D, Banerjee A, Christians KK, Turaga KK, Pawlik TM, Clark Gamblin T) Ann Surg Oncol 2015 Mar 17: PMID 25777092
  • Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. (Jayakrishnan TT, Nadeem H, Groeschl RT, George B, Thomas JP, Ritch PS, Christians KK, Tsai S, Evans DB, Pappas SG, Gamblin TC, Turaga KK) HPB (Oxford) 2015 Feb;17(2):131-9 PMID 25123702
  • Molecular profiling in gastric cancer: examining potential targets for chemotherapy. (Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC) J Surg Oncol 2014 Sep;110(3):302-6 PMID 24844210
  • Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. (Hwang M, Jayakrishnan TT, Green DE, George B, Thomas JP, Groeschl RT, Erickson B, Pappas SG, Gamblin TC, Turaga KK) Eur J Cancer 2014 Jul;50(10):1747-57 PMID 24767470
  • Management of acute cholecystitis in cancer patients: a comparative effectiveness approach. (Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Pappas S, Gamblin TC, Turaga KK) Surg Endosc 2014 May;28(5):1505-14 PMID 24687416
  • Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? (Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B) Oncologist 2014 Mar;19(3):266-74 PMID 24569947
  • Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiency. (Cornell RF, Kelly DF, Bordo G, Carroll TB, Duong HT, Kim J, Takasumi Y, Thomas JP, Wong YL, Findling JW) Case Rep Endocrinol 2013;2013:675298 PMID 24455332
  • Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis. (Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Clark Gamblin T, Turaga KK) Ann Surg Oncol 2014 Jan;21(1):240-7 PMID 24114054
  • Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. (Kolesar JM, Sachidanandam K, Schelman WR, Eickhoff J, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE) Exp Ther Med 2011 1;2(1):119-123 PMID 21373381
  • A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. (Lubner SJ, Loconte NK, Holen KD, Schelman W, Thomas JP, Jumonville A, Eickhoff JC, Seo S, Mulkerin DL) Clin Colorectal Cancer 2010 Jul;9(3):157-61 PMID 20643620
  • The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. (Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD) Cancer Chemother Pharmacol 2010 Oct;66(5):973-80 PMID 20127092
  • Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. (Traynor AM, Thomas JP, Ramanathan RK, Mody TD, Alberti D, Wilding G, Bailey HH) Invest New Drugs 2011 Apr;29(2):316-22 PMID 19997959
  • Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. (Saif MW, Oettle H, Vervenne WL, Thomas JP, Spitzer G, Visseren-Grul C, Enas N, Richards DA) Cancer J 2009 Jul-Aug;15(4):339-43 PMID 19672152
  • Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. (Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS) Oncology 2009;76(5):333-7 PMID 19307739
  • A phase I study of an oral simulated FOLFOX with high dose capecitabine. (Mulkerin D, LoConte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G) Invest New Drugs 2009 Oct;27(5):461-8 PMID 19129971
  • A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. (LoConte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J) Cancer Chemother Pharmacol 2008 Dec;63(1):109-15 PMID 18322686
  • Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma. (Attia S, Holen KD, Thomas JP, Richie K, Dzelak T, Teeter K, Warren D, Bilger A, Fine J, Eickhoff J, Drinkwater N, Mulkerin D, Morgan-Meadows S) Clin Adv Hematol Oncol 2008 Jan;6(1):44-54 PMID 18322441
  • A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. (Schelman W, Morgan-Meadows S, Bailey H, Holen K, Thomas JP, Eickhoff J, Brandon H, Oliver K, Alberti D, Wilding G) Cancer Chemother Pharmacol 2008 Sep;62(4):727-33 PMID 18172649
  • Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. (Kolesar JM, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE) J Inorg Biochem 2008 Apr;102(4):693-8 PMID 18061679
  • Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. (Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ) J Clin Oncol 2007 Aug 10;25(23):3456-61 PMID 17687149
  • Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. (Bailey HH, Alberti DB, Thomas JP, Mulkerin DL, Binger KA, Gottardis MM, Martell RE, Wilding G) Clin Cancer Res 2007 Jun 15;13(12):3623-9 PMID 17510207
  • Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. (Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A 3rd, Espat J, Bilbao JI, Sharma RA, Thomas JP, Coldwell D) Int J Radiat Oncol Biol Phys 2007 May 1;68(1):13-23 PMID 17448867
  • Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. (McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G) Clin Cancer Res 2005 Nov 1;11(21):7851-60 PMID 16278408
  • A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. (Morgan-Meadows S, Mulkerin D, Berlin JD, Kim K, Bailey H, Saphner T, Jumonville A, Hansen R, Ahuja H, McFarland T, Thomas JP) Oncology 2005;69(2):130-4 PMID 16118509
  • A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. (Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA) Clin Cancer Res 2005 May 1;11(9):3410-6 PMID 15867242
  • Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group. (Shepard RC, Levy DE, Berlin JD, Stuart K, Harris JE, Aviles V, Thomas JP, Benson AB 3rd) Oncology 2004;66(4):303-9 PMID 15218298
  • Gemcitabine, Paclitaxel, and piritrexim: a phase I study. (Liu G, Bailey HH, Arzoomanian RZ, Alberti D, Binger K, Volkman J, Feierabend C, Marnocha R, Wilding G, Thomas JP) Am J Clin Oncol 2003 Jun;26(3):280-4 PMID 12796601
  • Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. (Meadows SM, Mulkerin D, Berlin J, Bailey H, Kolesar J, Warren D, Thomas JP) Int J Gastrointest Cancer 2002;32(2-3):125-8 PMID 12794248
  • Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. (Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G) J Clin Oncol 2003 Jan 15;21(2):223-31 PMID 12525513
  • Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. (Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G) Cancer Chemother Pharmacol 2002 Dec;50(6):465-72 PMID 12451473
  • Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy. (Morgan-Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G) Invest New Drugs 2002 Nov;20(4):377-82 PMID 12448654
  • Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. (Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd) J Clin Oncol 2002 Aug 1;20(15):3270-5 PMID 12149301
  • Phase I clinical and pharmacokinetic trial of irofulven. (Thomas JP, Arzoomanian R, Alberti D, Feierabend C, Binger K, Tutsch KD, Steele T, Marnocha R, Smith C, Smith S, MacDonald J, Wilding G, Bailey H) Cancer Chemother Pharmacol 2001 Dec;48(6):467-72 PMID 11800027
  • Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. (Carbone PP, Pirsch JD, Thomas JP, Douglas JA, Verma AK, Larson PO, Snow S, Tutsch KD, Pauk D) Cancer Epidemiol Biomarkers Prev 2001 Jun;10(6):657-61 PMID 11401916
  • Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. (Ochoa L, Hurwitz HI, Wilding G, Cohen D, Thomas JP, Schwartz G, Monroe P, Petros WP, Ertel VP, Hsieh A, Hoffman C, Drengler R, Magnum S, Rowinsky EK) Ann Oncol 2000 Oct;11(10):1313-22 PMID 11106122
  • Nitric oxide donor compounds inhibit the toxicity of oxidized low-density lipoprotein to endothelial cells. (Struck AT, Hogg N, Thomas JP, Kalyanaraman B) FEBS Lett 1995 Mar 20;361(2-3):291-4 PMID 7698340
  • Involvement of preexisting lipid hydroperoxides in Cu(2+)-stimulated oxidation of low-density lipoprotein. (Thomas JP, Kalyanaraman B, Girotti AW) Arch Biochem Biophys 1994 Dec;315(2):244-54 PMID 7986064
  • The role of photodynamic therapy in posterior fossa brain tumors. A preclinical study in a canine glioma model. (Whelan HT, Schmidt MH, Segura AD, McAuliffe TL, Bajic DM, Murray KJ, Moulder JE, Strother DR, Thomas JP, Meyer GA) J Neurosurg 1993 Oct;79(4):562-8 PMID 8410226
  • Hyperexpression of catalase in selenium-deprived murine L1210 cells. (Lin F, Thomas JP, Girotti AW) Arch Biochem Biophys 1993 Aug 15;305(1):176-85 PMID 8342949
  • Lethal damage to endothelial cells by oxidized low density lipoprotein: role of selenoperoxidases in cytoprotection against lipid hydroperoxide- and iron-mediated reactions. (Thomas JP, Geiger PG, Girotti AW) J Lipid Res 1993 Mar;34(3):479-90 PMID 8468531
  • Intracellular catalase inhibition does not predispose rat heart to ischemia-reperfusion and hydrogen peroxide-induced injuries. (Konorev EA, Struck AT, Baker JE, Ramanujam S, Thomas JP, Radi R, Kalyanaraman B) Free Radic Res Commun 1993;19(6):397-407 PMID 8168729
  • Lethal damage to murine L1210 cells by exogenous lipid hydroperoxides: protective role of glutathione-dependent selenoperoxidases. (Geiger PG, Thomas JP, Girotti AW) Arch Biochem Biophys 1991 Aug 1;288(2):671-80 PMID 1898056
  • Reactivity of phospholipid hydroperoxide glutathione peroxidase with membrane and lipoprotein lipid hydroperoxides. (Maiorino M, Thomas JP, Girotti AW, Ursini F) Free Radic Res Commun 1991;12-13 Pt 1:131-5 PMID 2071029
  • Enzymatic reduction of phospholipid and cholesterol hydroperoxides in artificial bilayers and lipoproteins. (Thomas JP, Geiger PG, Maiorino M, Ursini F, Girotti AW) Biochim Biophys Acta 1990 Aug 6;1045(3):252-60 PMID 2386798
  • Protective action of phospholipid hydroperoxide glutathione peroxidase against membrane-damaging lipid peroxidation. In situ reduction of phospholipid and cholesterol hydroperoxides. (Thomas JP, Maiorino M, Ursini F, Girotti AW) J Biol Chem 1990 Jan 5;265(1):454-61 PMID 2294113
  • Role of lipid peroxidation in hematoporphyrin derivative-sensitized photokilling of tumor cells: protective effects of glutathione peroxidase. (Thomas JP, Girotti AW) Cancer Res 1989 Apr 1;49(7):1682-6 PMID 2522345
  • Glucose administration augments in vivo uptake and phototoxicity of the tumor-localizing fraction of hematoporphyrin derivative. (Thomas JP, Girotti AW) Photochem Photobiol 1989 Mar;49(3):241-7 PMID 2525259
  • Reactivity of photochemically-generated lipid hydroperoxides in cell membranes with glutathione peroxidase. (Thomas JP, Girotti AW) Photochem Photobiol 1989 Feb;49(2):153-6 PMID 2523541
  • Photooxidation of cell membranes in the presence of hematoporphyrin derivative: reactivity of phospholipid and cholesterol hydroperoxides with glutathione peroxidase. (Thomas JP, Girotti AW) Biochim Biophys Acta 1988 Oct 14;962(3):297-307 PMID 2971397
  • Ascorbate-enhanced lipid peroxidation in photooxidized cell membranes: cholesterol product analysis as a probe of reaction mechanism. (Bachowski GJ, Thomas JP, Girotti AW) Lipids 1988 Jun;23(6):580-6 PMID 3172988
  • Beneficial effects of iloprost in the stunned canine myocardium. (Farber NE, Pieper GM, Thomas JP, Gross GJ) Circ Res 1988 Feb;62(2):204-15 PMID 2448057
  • Singlet oxygen intermediacy in the photodynamic action of membrane-bound hematoporphyrin derivative. (Thomas JP, Hall RD, Girotti AW) Cancer Lett 1987 Jun;35(3):295-302 PMID 2954632
  • Photodynamic action of merocyanine 540 on artificial and natural cell membranes: involvement of singlet molecular oxygen. (Kalyanaraman B, Feix JB, Sieber F, Thomas JP, Girotti AW) Proc Natl Acad Sci U S A 1987 May;84(9):2999-3003 PMID 3033673
  • Inhibition of cell membrane lipid peroxidation by cadmium- and zinc-metallothioneins. (Thomas JP, Bachowski GJ, Girotti AW) Biochim Biophys Acta 1986 Dec 10;884(3):448-61 PMID 3778934
  • Xanthine oxidase-catalyzed crosslinking of cell membrane proteins. (Girotti AW, Thomas JP, Jordan JE) Arch Biochem Biophys 1986 Dec;251(2):639-53 PMID 3800391
  • Prooxidant and antioxidant effects of ascorbate on photosensitized peroxidation of lipids in erythrocyte membranes. (Girotti AW, Thomas JP, Jordan JE) Photochem Photobiol 1985 Mar;41(3):267-76 PMID 4011692
  • Lipid photooxidation in erythrocyte ghosts: sensitization of the membranes toward ascorbate- and superoxide-induced peroxidation and lysis. (Girotti AW, Thomas JP, Jordan JE) Arch Biochem Biophys 1985 Jan;236(1):238-51 PMID 2981506
  • Inhibitory effect of zinc(II) on free radical lipid peroxidation in erythrocyte membranes. (Girotti AW, Thomas JP, Jordan JE) J Free Radic Biol Med 1985;1(5-6):395-401 PMID 3841804
  • Damaging effects of oxygen radicals on resealed erythrocyte ghosts. (Girotti AW, Thomas JP) J Biol Chem 1984 Feb 10;259(3):1744-52 PMID 6546380
  • Superoxide and hydrogen peroxide-dependent lipid peroxidation in intact and triton-dispersed erythrocyte membranes. (Girotti AW, Thomas JP) Biochem Biophys Res Commun 1984 Jan 30;118(2):474-80 PMID 6322749
  • Last update: 06/01/2015